ClinicalTrials.gg
Active, not recruitingNCT04521231Updated May 28, 2026

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

A Phase 1/2 interventional study of Blinatumomab in B Cell Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Active, not recruiting at 109 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Primary conditionNeoplasm, ResidualRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm, Residual
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's title name Neoplasm, Residual.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
181
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing blinatumomab in Neoplasm, Residual — 3 open to participants now, 6 under way, none of them phase 3. blinatumomab · Neoplasm, Residual.

Enrollment
2nd of 17
181 · median 31
Started
2021
with 3 others
Phase 1/2
3 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
3 of 17
Amgen

Among the 17 studies testing blinatumomab in Neoplasm, Residual, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1/2, and was the 9th registered.

Neoplasm, Residual

293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

Browse Neoplasm, Residual studies →

Open to participants now

3 of the 17 studies testing blinatumomab in Neoplasm, Residual are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Neoplasm, Residual studies recruiting now, 58 (63%) set no upper age limit and 23 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing blinatumomab in Neoplasm, Residual, or all of them as a file.
02

Study summary

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab.

The Phase II part of the study will evaluate the safety, efficacy, and tolerability of SC blinatumomab for treatment of R/R B-ALL and Minimum Residual Disease Positive (MRD+) B-ALL in participants 12 years old and greater. It will also conduct a clinical pharmacokinetic (PK) evaluation of SC1 and SC2 blinatumomab formulations.

03

Conditions studied

  • B Cell Precursor Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • R/R B-ALL
  • MRD+ B-ALL
  • Relapsed
  • Refractory
  • Minimal Residual Disease
  • AMG 103
  • Blinatumomab
  • Acute lymphoblastic leukemia
  • Adolescent
  • Adult
04

In context

Neoplasm, Residual Reclassified

293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

This study's enrollment of 181 is above the median of 50 across 198 interventional studies indexed under Neoplasm, Residual.

Browse Neoplasm, Residual studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Neoplasm, Residual, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ph-IIC, Dose Escalation and Dose Expansion: Aged 18 years or older (or same or greater than legal age within the country if it is older than 18 years).
  • Ph-IIRa and Ph-IIMa: Aged ≥ 17 years at time of .
  • Ph-IIRb and Ph-IIMb: Age ≥ 12 years and \< 17 years at time of informed consent.
  • Ph-IIR, Ph-IIC, Dose escalation, Dose Expansion: Participants with R/R B-precursor ALL.
  • B-precursor ALL at any time after first salvage therapy.
  • Relapsed B-precursor ALL at any time after allogenic hematopoietic stem cell transplant ().
  • Ph-IIR, Ph-IIC, Dose escalation, Dose expansion: Greater than or equal to 5% blasts in the Bone Marrow per local assessment.
  • Ph-IIM: B-precursor ALL and bone marrow blasts (BMB) ≥ 0.01% and \< 5% per local assessment.
  • Ph-IIM: Availability of an appropriate archival BM specimen from initial or relapse diagnosis and the screening BM sample.
  • Participants aged ≥ 18 years: (ECOG) Performance Status less than or equal to 2.
  • Participants aged 16 to \< 18 years old: Performance Score ≥ 50%.
  • Participants aged \< 16 years old: Lansky Performance Score ≥ 50%.
  • Any Ph+ participant intolerant or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible.
  • Ph-IIM: BM function as follows:

    • (ANC) ≥ 500/μL
    • count ≥ 50 000/μL (transfusion permitted)
    • level ≥ 9 g/dL (transfusion permitted)

The above is a summary, other inclusion criteria details may apply.

Exclusion criteria

Exclusion Criteria:

  • Active ALL in the central nervous system (CNS). Presence of greater than 5 white blood cells per cubic millimeter in cerebrospinal fluid (CSF) with lymphoblasts present and/or clinical signs of CNS leukemia. If CSF leukemia is present subjects will have to receive intrathecal therapy and have documented negative CSF prior to enrolling.
  • History or presence of CNS pathology (excluding headache) such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or severe (≥ grade 3) CNS events including immune effector cell-associated neurotoxicity syndrome (ICANS) from prior chimeric antigen receptor T-cell (CAR T) or other T cell engager therapies.
  • Isolated Extramedullary (EM) Disease.
  • For Ph-IIM only: Current EM disease or presence of circulating leukemia blasts.
  • Current disease or history of autoimmune disease with potential CNS involvement.
  • Active acute or chronic requiring systemic treatment with medication.
  • Symptoms and/or signs that indicate an acute or uncontrolled chronic infection, any other disease or condition that could be exacerbated by the treatment or would complicate protocol compliance.
  • Testicular leukemia.
  • History of (with certain exceptions) other than ALL within 3 years prior to start of protocol-specified therapy.
  • HSCT within 12 weeks before the start of protocol-specified therapy.
  • Cancer chemotherapy within 2 weeks before the start of protocol-specified therapy (with certain exceptions).
  • Immunotherapy within 4 weeks before start of protocol-specified therapy.
  • Prior failed cluster of differentiation (CD19) directed therapy such as prior blinatumomab or CD19 CAR T cells will be allowed (with demonstrated continued CD19+ expression), if treatment ended more than 4 weeks prior to start of protocol therapy and no prior CNS complications.
  • Currently receiving treatment in or less than 30 days or 5 half-lives since ending treatment on another study(ies).
  • Abnormal screening laboratory parameters.
  • Female participant: Pregnant or breastfeeding or planning to become pregnant or donate eggs, or expected to breastfeed during treatment and for 96 hours after the last dose of investigational product (SC blinatumomab).

The above is a summary, other exclusion criteria details may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Dose Escalation Phase: Blinatumomab Subcutaneous Formulation 1 (SC1)

    Cohorts of at least 3 adult participants with R/R B-ALL will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.

    Drug: Blinatumomab

  • Experimental
    Dose Expansion Phase: Blinatumomab SC1

    Up to 4 cohorts of adult participants with R/R B-ALL will be enrolled at different dose levels to support identification of the RP2D. Each cohort will aim to further assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy.

    Drug: Blinatumomab

  • Experimental
    Ph-IIC: Clinical PK Evaluation of SC Blinatumomab Formulations

    1 cohort of adult participants will be enrolled into the Ph-IIC arm. The clinical PK evaluation cohort (Ph-IIC) will be conducted to compare the PK of SC1 and SC2 formulations at the preliminary RP2D determined from the dose expansion phase, in participants with R/R B-ALL.

    Drug: Blinatumomab

  • Experimental
    Ph-IIR: Efficacy of SC Blinatumomab in Participants with R/R B-ALL

    The efficacy of SC blinatumomab (in the SC2 formulation) will be evaluated in adults and adolescents with R/R B-ALL.

    Drug: Blinatumomab

  • Experimental
    Ph-IIM: Efficacy of SC Blinatumomab in Participants with MRD+ B-ALL

    The efficacy of SC blinatumomab (in the SC2 formulation) will be evaluated in adults and adolescents with MRD+ B-ALL.

    Drug: Blinatumomab

Interventions

  • Blinatumomab will be administered as a subcutaneous (SC) injection.

    Also known as: AMG 103

07

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Number of participants who experience dose limiting toxicities (DLTs)

    Time frame: Up to 29 days

  2. Dose Escalation Phase: Number of participants who experience one or more treatment-emergent adverse events (TEAEs)

    Time frame: Up to approximately 28 weeks

  3. Dose Escalation Phase: Number of participants who experience one or more serious TEAEs

    Time frame: Up to approximately 28 weeks

  4. Dose Escalation Phase: Number of participants who experience one or more treatment-related TEAEs

    Time frame: Up to approximately 28 weeks

  5. Dose Escalation Phase: Number of participants who experience one or more adverse events (AEs) of Interest (AEIs)

    Time frame: Up to approximately 28 weeks

  6. Dose Expansion and Phase 2 Ph-IIR cohort: Number of participants who achieve complete remission (CR) / complete remission with partial hematological recovery (CRh)

    Time frame: Up to 10 weeks

  7. Phase 2 Ph-IIC cohort: Maximum concentration (Cmax) of blinatumomab SC1 and SC2

    Time frame: Up to approximately 4 weeks

  8. Phase 2 Ph-IIC cohort: Average concentration (Cavg) of blinatumomab SC1 and SC2

    Time frame: Up to approximately 4 weeks

  9. Phase 2 Ph-IIC cohort: Time to reach maximum concentration (Tmax) of blinatumomab SC1 and SC2

    Time frame: Up to approximately 4 weeks

  10. Phase 2 Ph-IIC cohort: Area under the concentration-time curve (AUC) of blinatumomab SC1 and SC2

    Time frame: Up to approximately 4 weeks

  11. Phase 2 Ph-IIM cohort: Number of participants who achieve CR with MRD-negative response

    Time frame: Up to 10 weeks

Secondary outcomes

  1. Dose Escalation and Dose Expansion Phase: Minimum concentration over the dosing interval (Cmin) of blinatumomab

    Time frame: Up to approximately 10 weeks

  2. Dose Escalation and Dose Expansion Phase: Cmax of blinatumomab

    Time frame: Up to approximately 10 weeks

  3. Dose Escalation and Dose Expansion Phase: Tmax of blinatumomab

    Time frame: Up to approximately 10 weeks

  4. Dose Escalation and Dose Expansion Phase: AUC of blinatumomab

    Time frame: Up to approximately 10 weeks

  5. Dose Escalation Phase and Phase 2 (Ph-IIC cohort): Number of participants who achieve CR/CRh

    Time frame: Up to 10 weeks

  6. Dose Escalation Phase, Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Number of participants with incidence of anti-blinatumomab antibody formation

    Time frame: Up to approximately 28 weeks

  7. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Overall survival (OS)

    Time frame: Up to approximately 2 years

  8. Dose Expansion Phase and Phase 2 (Ph-IIR cohort and Ph-IIC cohort): Duration of response

    Time frame: Up to approximately 2 years

  9. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Relapse free survival

    Time frame: Up to approximately 2 years

  10. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Number of participants who experience one or more TEAEs

    Time frame: Up to approximately 28 weeks

  11. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Number of participants who experience one or more serious treatment-emergent adverse event

    Time frame: Up to approximately 2 years

  12. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Number of participants who experience one or more treatment-related treatment-emergent adverse events

    Time frame: Up to approximately 28 weeks

  13. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Number of participants who experience one or more AEIs

    Time frame: Up to approximately 28 weeks

  14. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Summary scores of quality of life at each assessment as assessed by the EORTC QLQ-C30 for participants aged ≥ 17 years at the time of consent

    The EORTC QLQ-C30 is defined as the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.

    Time frame: Baseline (Day 1) up to approximately 28 weeks

  15. Dose Expansion Phase and Phase 2 (Ph-IIR cohort, Ph-IIM cohort and Ph-IIC cohort): Change from baseline of quality of life as assessed by the EORTC QLQ-C30 for participants aged ≥ 17 years at the time of consent

    Time frame: Baseline (Day 1) up to approximately 28 weeks

  16. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Summary scores of quality of life at each assessment as assessed by PedsQL Generic Core Scale for participants aged 12 to < 17 years at time of consent

    Time frame: Baseline (Day 1) up to approximately 28 weeks

  17. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Change from baseline of quality of life as assessed by PedsQL Generic Core Scale for participants aged 12 to < 17 years at time of consent

    Time frame: Baseline (Day 1) up to approximately 28 weeks

  18. Phase 2 (Ph-IIR cohort): Number of participants who achieve CR

    Time frame: Up to 10 weeks

  19. Phase 2 (Ph-IIR cohort): Number of participants who achieve CR, CRh, CRi (complete remission with incomplete hematological recovery) or blast free hypoplastic or aplastic bone marrow (BM)

    Time frame: Up to 10 weeks

  20. Phase 2 (Ph-IIM cohort): Number of participants who achieve CR, CRh, CRi or blast free hypoplastic or aplastic BM with MRD-negative response

    Time frame: Up to 10 weeks

  21. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Number of participants who achieve CR or CRh with MRD-negative response

    Time frame: Up to 10 weeks

  22. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Duration of molecular response

    Time frame: Up to approximately 2 years

  23. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Cmax of blinatumomab for participants participating in intense PK sampling assessment

    Time frame: Up to approximately 4 weeks

  24. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Tmax of blinatumomab for participants participating in intense PK sampling assessment

    Time frame: Up to approximately 4 weeks

  25. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): AUC of blinatumomab for participants participating in intense PK sampling assessment

    Time frame: Up to approximately 4 weeks

  26. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Blinatumomab serum concentrations for participants not participating in intense PK sampling assessment

    Time frame: Up to approximately 4 weeks

  27. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Proportion of time on treatment with high side effect bother from baseline to end of treatment as measured by Functional Assessment of Chronic Illness Therapy (FACIT) GP5 item for participants aged ≥ 17 years

    This endpoint applies to participants aged ≥ 17 years at time of consent.

    Time frame: Baseline (Day 1) up to approximately 28 weeks

  28. Phase 2 (Ph-IIR cohort and Ph-IIM cohort): Pain difference between pain score before and after injection as reported using the Numeric Rating Scale (NRS-11) for participants aged 12 to < 17 years at time of consent

    Time frame: Up to approximately 28 weeks

08

Study locations

109 sites

Showing the first 100 of 109 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jabbour E, Zugmaier G, Agrawal V, Martinez-Sanchez P, Rifon Roca JJ, Cassaday RD, Boll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Diaz MT, Vucinic V, Gonzalez-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernandez-Rivas JM, Gordon PR, Bruggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr;99(4):586-595. doi: 10.1002/ajh.27227. Epub 2024 Feb 5. PubMed 38317420 ↗
  • Jabbour E, Lussana F, Martinez-Sanchez P, Torrent A, Rifon JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernandez-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Boll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, Gonzalez-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Lancet Haematol. 2025 Jul;12(7):e529-e541. doi: 10.1016/S2352-3026(25)00144-9. Epub 2025 Jun 15. PubMed 40532723 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Nov 2027, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 20, 2020
StartActual
Jan 4, 2021
Primary completionEst.
Nov 24, 2027
CompletionEst.
May 25, 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04521231
Lead sponsor
Amgen
Collaborators
BeOne Medicines
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Jan 4, 2021
Primary completion
Nov 24, 2027 (estimated)
Completion
May 25, 2029 (estimated)
Last update
May 28, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion